Published in

Springer (part of Springer Nature), Breast Cancer Research and Treatment, 2(160), p. 261-267

DOI: 10.1007/s10549-016-3985-7

Links

Tools

Export citation

Search in Google Scholar

Treatment with aromatase inhibitors and markers of cardiovascular disease

Journal article published in 2016 by Eva E. Blondeaux, Debora D. Musio, Paolo Bruzzi, Matteo Lambertini, Valerio Gazzola, Maria Cecilia M. C. Perfumo, Francesca Poggio ORCID, Claudia Bighin, Stefania S. Vecchio, Alessia D’Alonzo, Sara Giraudi, Alessia Levaggi, Domenico D. Palombo, Lucia Del Mastro, Alessia D'Alonzo
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Purpose: The cardiovascular effects of estrogen deprivation induced by aromatase inhibitors are unknown. We carried out a cross-sectional study to evaluate the effect of estrogen deprivation induced by aromatase inhibitors on markers of cardiovascular risk. Methods: We enrolled 410 postmenopausal women: 200 consecutive breast cancer patients treated with aromatase inhibitors for a median of 53 months (range 23–122) and 210 volunteer controls. Carotid intima-media thickness, presence of carotid stenosis, and presence of abdominal aortic aneurism were evaluated through an ultrasound examination. Results: Average carotid intima-media thickness was 0.97 ± 0.02 mm and 1.08 ± 0.02 mm for breast cancer group and control group, respectively (p